Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D (1989) Cancer Res 49: 6832-9 Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM (1990) Cancer Res 50: 2683-91 A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM (1994) Ann Oncol 5: 447-52 CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo. Assarsson E, Kambayashi T, Sandberg JK, Hong S, Taniguchi M, Van Kaer L, Ljunggren HG, Chambers BJ (2000) J Immunol 165: 3673-9 The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM (1990) Cancer 66: 2457-64 Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates beta 2 integrins on lymphokine-activated killer cells. Piali L, Albelda SM, Baldwin HS, Hammel P, Gisler RH, Imhof BA (1993) Eur J Immunol 23: 2464-71 In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. Sosman JA, Hank JA, Sondel PM (1990) Semin Oncol 17: 22-30; discussion 38-41 Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM (1990) Cancer Immunol Immunother 31: 53-9 Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2. Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL (1998) J Immunother 21: 85-94 Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma. Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR (1991) Cancer Invest 9: 35-48 Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J, Cytokine Working Group (2001) Med Oncol 18: 197-207
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.